TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Stock Crashes Amid Failed Study, Wedbush Downgrade
Wedbush Downgrades Alto Neuroscience to Neutral Following ALTO-100 Readout
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Alto Neuroscience Is Maintained at Outperform by Baird
Alto Neuroscience Analyst Ratings
Alto Neuroscience Downgraded to Neutral From Buy at Rodman & Renshaw
Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical Developments
Alto Neuroscience Analyst Ratings
Wedbush Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $29
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Analysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)
Wedbush Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $29
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $33
Alto Neuroscience, Inc. (ANRO) Gets a Buy From Jefferies
Buy Rating Affirmed for Alto Neuroscience, Inc. on Strong Clinical Trials and Strategic Precision Neuroscience Approach